Clinical trials
Recurrent clinical trials
Below are recruiting recurrent clinical trials, each written for real people, not researchers. We’re tracking 1,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07608653Recruiting
Minimally invasive surgery for recurrent groin hernias
This trial tests a keyhole (laparoscopic) surgical technique to repair inguinal hernias that have returned after previous surgery. The goal is to evaluate how well this approach works and what outcomes patients experience.
SohagAges Any age - NCT06609850Recruiting
Comparing TACE plus lenvatinib with or without ablation for recurrent liver cancer
This trial compares two treatments for people whose liver cancer has come back (recurrent intermediate-stage hepatocellular carcinoma). One group gets TACE plus lenvatinib (a targeted therapy), the other gets TACE plus lenvatinib plus ablation (a procedure that destroys tumors with heat or cold). The goal is to see which combination works better.
Beijing, None SelectedAges 18–75 - NCT06609876Recruiting
Donafenib after ablation for recurrent liver cancer
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
Beijing, None SelectedAges 18–75 - NCT07594015RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent endometrial cancer
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
Miami, FloridaAges 18 years+ - NCT07579208RecruitingPhase 1
CAR NK cells for recurrent glioblastoma brain tumors
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
Houston, TexasAges 18 years+ - NCT06430983Recruiting
Relearning liver cancer: a study of recurrent cases
This trial studies patients with liver cancer, including both the common type (hepatocellular carcinoma) and other types. It aims to understand the cancer better by collecting blood samples and medical information.
Nanjing, JiangsuAges 18–75 - NCT06719232Recruiting
Testing a new way to give bladder treatment without a catheter
This study tests a catheter-free method for delivering medication directly into the bladder. It may help patients with bladder pain, recurrent infections, bladder cancer, or cystitis after radiation or chemotherapy.
BudapestAges 18–80 - NCT05989178Recruiting
Recurrent Pregnancy Loss Registry
This study is a registry for people who have had repeated pregnancy losses. It will collect information to better understand and help manage this condition.
Vancouver, British ColumbiaAges 15–49 - NCT07551336RecruitingPhase 1
CAR-NK cells for recurrent glioblastoma and high-grade brain tumors
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
Shenzhen, GuangdongAges 18–75 - NCT07541781RecruitingPhase 1
Sitagliptin for recurrent grade 4 glioma
This trial tests whether the diabetes drug sitagliptin (Januvia) can help slow or shrink a recurrent grade 4 glioma (a type of brain tumor). It's for people whose tumor has come back after standard treatment and who have not used sitagliptin or Avastin before.
Iowa City, IowaAges 18 years+ - NCT07538128RecruitingEarly Phase 1
New drug YSCH-01 with immunotherapy for recurrent brain cancer
This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07518966Recruiting
Heart Rhythm Treatment Success Tracking Study
This study follows patients getting a newer heart rhythm treatment called pulsed field ablation for atrial fibrillation (an irregular heartbeat). Researchers want to understand which patients do well long-term and which may need additional treatment.
Chengdu, SichuanAges 18 years+ - NCT07501559RecruitingPhase 1/Phase 2
Study of JL15003 for recurrent glioblastoma
This trial is testing a new drug (JL15003) given directly into the brain tumor using a small device called an Ommaya reservoir. It is for people whose glioblastoma has come back despite standard treatments. You will need to have had a polio vaccine booster before starting.
ShanghaiAges 18 years+ - NCT06767332Recruiting
EMDR for fear of cancer returning in familial melanoma
This study tests whether EMDR therapy can help reduce the fear of cancer coming back in people who have been diagnosed with familial melanoma. If you often worry about your cancer returning, this treatment might help you feel more at ease.
Leiden, South HollandAges 18 years+ - NCT06762782RecruitingPhase 2
Lenvatinib after liver cancer surgery to prevent recurrence
This trial tests whether taking lenvatinib after liver cancer surgery can lower the chance of the cancer coming back. It is for people who have a high risk of recurrence and have recently had their liver tumor completely removed.
Nanjing, JiangsuAges 18–80 - NCT06657690RecruitingPhase 2
New drug combo for advanced nasopharyngeal cancer after immunotherapy
This trial tests a combination of two drugs, irinotecan liposome and S-1, for people with a type of nose and throat cancer that has spread or come back after treatment with immunotherapy (PD-1/L1 inhibitors). The goal is to see if this new combination can help when standard treatments have stopped working.
Zhuhai, GuangzhouAges 18–70 - NCT07494864Recruiting
Urinary tract health and microbiome study
This study looks at how bacteria and the immune system affect the lower urinary tract. It includes healthy volunteers and people with various urinary conditions, like infections or bladder pain.
Zurich, Canton of ZurichAges 18 years+ - NCT07495384Recruiting
CapsuleX and cisplatin for platinum-resistant ovarian cancer
This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.
Changchun, JilinAges 18 years+ - NCT06472713RecruitingPhase 2
Liposomal mitoxantrone with immunotherapy for advanced nasopharyngeal cancer
This trial tests a combination of a chemotherapy drug (mitoxantrone liposome) with an immunotherapy (PD-1 blocker) for people whose nasopharyngeal cancer has come back or spread and hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Zhuhai, GuangdongAges 18–70 - NCT07480941RecruitingPhase 1
CAR-NK cell therapy for recurrent glioblastoma
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
Shenzhen, GuangdongAges 18–75 - NCT07480954RecruitingPhase 1/Phase 2
CAR-NK cell therapy for recurrent ovarian cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.
Shenzhen, GuangdongAges 18–75 - NCT06640725RecruitingPhase 2
TPEx chemo with maintenance immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy drugs (TPEx) followed by two immunotherapy drugs (avelumab and cetuximab) as a first treatment for head and neck cancer that has spread or come back. It is for people whose tumors show a protein called PD-L1 and who have not had chemotherapy for advanced disease before.
Vandœuvre-lès-NancyAges 18–74 - NCT06657131Recruiting
PSMA PET scan for prostate cancer recurrence
This trial looks at how well a special PET scan (called PSMA PET) can find prostate cancer that has come back after treatment. It uses a radioactive tracer to spot cancer cells. Your doctor may already have ordered this scan as part of your regular care.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT07472153RecruitingPhase 2/Phase 3
Immunotherapy plus chemo for advanced cervical cancer
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Minsk, LesnoyAges 18–75
Hear when a new Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent?
- Yes. Clin2 currently lists 1,384 recruiting recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.